A Single Center, Phase 2B, Randomized, Double Blind, Study to Assess the Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain

Trial Profile

A Single Center, Phase 2B, Randomized, Double Blind, Study to Assess the Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs ALLOD 2 (Primary)
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Acronyms ANODYNE-4
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 17 Oct 2018 to 1 Oct 2018.
    • 11 Jul 2017 Planned primary completion date changed from 17 Jul 2018 to 1 Jul 2018.
    • 11 Jul 2017 Planned initiation date changed from 17 Jul 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top